Abstract | BACKGROUND: OBJECTIVES: PATIENTS AND METHODS: Six patients with recalcitrant pemphigus were treated. Rituximab was administered intravenously at a dosage of 375 mg/m2 body surface once weekly for 4 weeks. RESULTS: CONCLUSIONS: This study highlights that rituximab is a valuable drug for refractory pemphigus, although the response of mucous membranes and cutaneous folds may be delayed.
|
Authors | Angelo V Marzano, Daniele Fanoni, Luigia Venegoni, Emilio Berti, Ruggero Caputo |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 214
Issue 4
Pg. 310-8
( 2007)
ISSN: 1421-9832 [Electronic] Switzerland |
PMID | 17460402
(Publication Type: Journal Article)
|
Copyright | 2007 S. Karger AG, Basel |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD19
- Autoantibodies
- DSG3 protein, human
- Desmoglein 1
- Desmoglein 3
- Immunologic Factors
- Rituximab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD19
(blood)
- Autoantibodies
(blood)
- B-Lymphocytes
(immunology)
- Desmoglein 1
(blood)
- Desmoglein 3
(blood)
- Female
- Humans
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Pemphigus
(drug therapy)
- Rituximab
- Treatment Outcome
|